EA201992685A1 - Раствор леводопы для инфузий - Google Patents
Раствор леводопы для инфузийInfo
- Publication number
- EA201992685A1 EA201992685A1 EA201992685A EA201992685A EA201992685A1 EA 201992685 A1 EA201992685 A1 EA 201992685A1 EA 201992685 A EA201992685 A EA 201992685A EA 201992685 A EA201992685 A EA 201992685A EA 201992685 A1 EA201992685 A1 EA 201992685A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- solution
- aqueous
- cns
- nervous system
- central nervous
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 3
- 229960004502 levodopa Drugs 0.000 title abstract 3
- 238000001802 infusion Methods 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 abstract 6
- 239000011550 stock solution Substances 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 239000003186 pharmaceutical solution Substances 0.000 abstract 3
- 239000000243 solution Substances 0.000 abstract 3
- 239000012062 aqueous buffer Substances 0.000 abstract 2
- 239000007853 buffer solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
В настоящем изобретении предложен водный фармацевтический раствор для применения для лечения заболеваний центральной нервной системы (ЦНС), содержащий по меньшей мере 5 мг/мл растворенной леводопы и имеющий рН в диапазоне от 3,0 до 8,5. Указанный раствор получен путем смешивания a) водного исходного раствора, содержащего леводопу, причем указанный исходный раствор имеет рН менее 2,8 при 25°C, и b) водного буферного раствора для повышения рН указанного исходного раствора, причем указанный буферный раствор имеет рН по меньшей мере 4,0 при 25°C. Водный фармацевтический раствор вводят субъекту, страдающему заболеванием центральной нервной системы (ЦНС), вскоре после смешивания водного исходного раствора и водного буферного раствора. Помимо этого, в настоящем изобретении предложен набор для введения водных фармацевтических растворов субъектам, страдающим заболеваниями центральной нервной системы (ЦНС).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1750707 | 2017-06-05 | ||
| PCT/EP2018/064774 WO2018224501A1 (en) | 2017-06-05 | 2018-06-05 | Levodopa infusion solution |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201992685A1 true EA201992685A1 (ru) | 2020-06-05 |
Family
ID=62567647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201992685A EA201992685A1 (ru) | 2017-06-05 | 2018-06-05 | Раствор леводопы для инфузий |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11633353B2 (ru) |
| EP (3) | EP4445953A3 (ru) |
| JP (2) | JP7134228B2 (ru) |
| KR (1) | KR102437003B1 (ru) |
| CN (1) | CN110753538A (ru) |
| AR (1) | AR112070A1 (ru) |
| AU (1) | AU2018280745B2 (ru) |
| BR (1) | BR112019025215A2 (ru) |
| CA (1) | CA3065990A1 (ru) |
| CY (1) | CY1124236T1 (ru) |
| DK (1) | DK3634384T3 (ru) |
| EA (1) | EA201992685A1 (ru) |
| ES (1) | ES2866981T3 (ru) |
| HR (1) | HRP20210599T1 (ru) |
| HU (1) | HUE054268T2 (ru) |
| IL (1) | IL271169B (ru) |
| LT (1) | LT3634384T (ru) |
| MX (1) | MX393807B (ru) |
| PL (1) | PL3634384T3 (ru) |
| PT (1) | PT3634384T (ru) |
| RS (1) | RS61749B1 (ru) |
| SI (1) | SI3634384T1 (ru) |
| SM (1) | SMT202100247T1 (ru) |
| TW (1) | TWI875677B (ru) |
| WO (1) | WO2018224501A1 (ru) |
| ZA (1) | ZA201908027B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4445953A3 (en) * | 2017-06-05 | 2025-01-29 | Dizlin Pharmaceuticals AB | Levodopa infusion solution |
| WO2020039262A1 (en) * | 2018-08-18 | 2020-02-27 | Ftf Pharma Private Limited | Pharmaceuticals solution for oral dosage |
| HU231668B1 (hu) * | 2021-12-28 | 2025-06-28 | Semmelweis Egyetem | Szemcsepp készítmény |
| EP4223288B1 (en) | 2022-02-07 | 2024-03-06 | Berlirem GmbH | Novel kit of pharmaceutical preparations for the treatment of parkinson's disease |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54105221A (en) | 1978-02-02 | 1979-08-18 | Sankyo Co Ltd | Preparation of stable concentrated dopa injection |
| SE512655C2 (sv) * | 1993-11-17 | 2000-04-17 | Medmera Sweden Hb C O Nil Dizd | Infusionslösning för medicinskt bruk innehållande L-dopa |
| DE19757224A1 (de) | 1997-12-22 | 1999-07-01 | Bayer Ag | Verfahren und Vorrichtung zur in-situ-Formulierung einer Arzneistofflösung zur parenteralen Applikation |
| CN1845728B (zh) * | 2003-08-29 | 2013-06-19 | 转化医药公司 | 包含左旋多巴和卡比多巴的药物组合物 |
| WO2005023185A2 (en) | 2003-08-29 | 2005-03-17 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| US8815950B2 (en) | 2003-08-29 | 2014-08-26 | Janssen Biotech, Inc. | Pharmaceutical compositions and method of using levodopa and carbidopa |
| SE0401842D0 (sv) | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| CN102438587B (zh) | 2009-05-19 | 2015-08-19 | 神经层有限公司 | 用于多巴脱羧酶抑制剂连续施用的组合物 |
| MX348225B (es) | 2010-11-15 | 2017-05-31 | Neuroderm Ltd | Administracion continua de levodopa, inhibidores de dopa decarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para la misma. |
| AU2011101361A4 (en) | 2010-11-15 | 2011-12-15 | Andrew Lumsden | A prefilled syringe for administering buffered lignocaine |
| CN102755252A (zh) | 2011-07-28 | 2012-10-31 | 辽宁海思科制药有限公司 | 一种新的包装氨基酸葡萄糖注射液的双室输液袋 |
| WO2014141261A1 (en) * | 2013-03-13 | 2014-09-18 | Neuroderm Ltd | Method for treatment of parkinson's disease |
| WO2015034870A2 (en) | 2013-09-03 | 2015-03-12 | Arocha Max | Double-chamber mixing syringe and method of use |
| EP4445953A3 (en) * | 2017-06-05 | 2025-01-29 | Dizlin Pharmaceuticals AB | Levodopa infusion solution |
-
2018
- 2018-06-05 EP EP24183451.4A patent/EP4445953A3/en active Pending
- 2018-06-05 SM SM20210247T patent/SMT202100247T1/it unknown
- 2018-06-05 BR BR112019025215-0A patent/BR112019025215A2/pt active Search and Examination
- 2018-06-05 CA CA3065990A patent/CA3065990A1/en active Pending
- 2018-06-05 WO PCT/EP2018/064774 patent/WO2018224501A1/en active Search and Examination
- 2018-06-05 IL IL271169A patent/IL271169B/en unknown
- 2018-06-05 AU AU2018280745A patent/AU2018280745B2/en active Active
- 2018-06-05 US US16/619,176 patent/US11633353B2/en active Active
- 2018-06-05 PL PL18730319T patent/PL3634384T3/pl unknown
- 2018-06-05 MX MX2019014675A patent/MX393807B/es unknown
- 2018-06-05 HU HUE18730319A patent/HUE054268T2/hu unknown
- 2018-06-05 AR ARP180101500A patent/AR112070A1/es unknown
- 2018-06-05 KR KR1020197037906A patent/KR102437003B1/ko active Active
- 2018-06-05 HR HRP20210599TT patent/HRP20210599T1/hr unknown
- 2018-06-05 TW TW107119351A patent/TWI875677B/zh active
- 2018-06-05 RS RS20210467A patent/RS61749B1/sr unknown
- 2018-06-05 LT LTEP18730319.3T patent/LT3634384T/lt unknown
- 2018-06-05 SI SI201830257T patent/SI3634384T1/sl unknown
- 2018-06-05 PT PT187303193T patent/PT3634384T/pt unknown
- 2018-06-05 DK DK18730319.3T patent/DK3634384T3/da active
- 2018-06-05 JP JP2020516960A patent/JP7134228B2/ja active Active
- 2018-06-05 ES ES18730319T patent/ES2866981T3/es active Active
- 2018-06-05 EA EA201992685A patent/EA201992685A1/ru unknown
- 2018-06-05 CN CN201880037143.6A patent/CN110753538A/zh active Pending
- 2018-06-05 EP EP21153018.3A patent/EP3838263A1/en not_active Withdrawn
- 2018-06-05 EP EP18730319.3A patent/EP3634384B1/en active Active
-
2019
- 2019-12-03 ZA ZA2019/08027A patent/ZA201908027B/en unknown
-
2021
- 2021-04-23 CY CY20211100353T patent/CY1124236T1/el unknown
-
2022
- 2022-06-29 JP JP2022104764A patent/JP7437450B2/ja active Active
-
2023
- 2023-02-28 US US18/175,599 patent/US12048764B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992685A1 (ru) | Раствор леводопы для инфузий | |
| EA201891565A1 (ru) | Соединения и композиции для лечения состояний, ассоциированных с активностью sting | |
| EA202090955A1 (ru) | Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови | |
| RU2470642C2 (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
| EA201991316A1 (ru) | Конъюгаты, содержащие двойной агонист glp-1/глюкагона, линкер и гиалуроновую кислоту | |
| EA202090871A1 (ru) | Ингибирование убиквитин-специфической пептидазы 30 | |
| EA201690069A1 (ru) | Применение высоких доз придопидина для лечения болезни хантингтона | |
| MA44612B1 (fr) | Méthodes de traitement de cancers pédiatriques | |
| MA48486B1 (fr) | Polymères liant les protons pour administration orale | |
| FI3672631T3 (fi) | Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia | |
| EA201792144A1 (ru) | Стабильный препарат для парентерального введения тапентадола | |
| ECSP21003707A (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
| MX390101B (es) | Tratamiento medico que comprende administracion enteral de edaravona | |
| BR112017025527A2 (pt) | preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe. | |
| JP7062804B2 (ja) | レビー小体病の治療および／または予防剤 | |
| PE20200889A1 (es) | METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa) | |
| EA200801299A1 (ru) | Фармацевтическая композиция в форме раствора для инъекций, обладающая церебровазодилатирующей и ноотропной активностью, и способ ее получения | |
| MA49754B1 (fr) | Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag | |
| BRPI0512151A (pt) | solução concentrada de sal de sódio monoidratado do tenatoprazol, composição farmacêutica, utilização do sal de sódio monoidratado do tenatoprazol, processo de preparação do sal de sódio monoidratado do tenatoprazol, e composição para administração por via oral do sal de sódio monoidratado do tenatoprazol | |
| EA201990744A1 (ru) | Стабильная лекарственная форма для парентерального введения тапентадола | |
| EA201791713A1 (ru) | Применение модифицированных полимеров глюкозы для снижения метастазирования опухолей | |
| EA202092756A1 (ru) | Конденсированные бициклические соединения для применения в качестве ингибиторов убиквитин-специфической пептидазы 30 | |
| EA201690788A1 (ru) | Фармацевтические лекарственные формы, содержащие натрий-1-[6-(морфолин-4-ил)пиримидин-4-ил]-4-(1h-1,2,3-триазол-1-ил)-1н-пиразол-5-олат | |
| RU2015138087A (ru) | Активный ингредиент лекарственного средства, лекарственное средство, фармацевтическая композиция и способ лечения демиелинизирующих заболеваний живого организма, включая профилактику заболевания | |
| EA201900272A2 (ru) | Композиция помалидомида для лечения заболеваний, ассоциированных с фно |